‘Time to Exit’: HSBC Downgrades UnitedHealth (UNH), Slashes Target to $270
Analyst Flags Rising Medical Costs, Regulatory Risks, and Uncertain Recovery Timeline
UnitedHealth Group (UNH) is under renewed pressure as HSBC analyst Sidharth Sahoo downgraded the stock from Hold to Sell, cutting the price target from $490 to $270—implying a 16% downside. The move comes amid a storm of earnings uncertainty, rising costs, and regulatory overhangs shaking investor confidence.
Why the Downgrade?
Sahoo cited three major red flags that prompted the bearish call:
- Rising Medical Loss Ratio (MLR):
- New estimates for 2025 show an MLR of 88.1%, higher than UnitedHealth’s earlier guidance of 87–88%.
- Suggests persistently high healthcare costs, which could extend margin pressure into 2026.
- Regulatory Headwinds for Optum:
- Ongoing debates around pharmacy benefit managers (PBMs) and the potential adoption of a most-favored nation (MFN) drug pricing model may significantly impact Optum’s revenue streams.
- These risks, Sahoo argues, are not fully priced into the stock.
- Guidance Withdrawal and CEO Transition:
- UnitedHealth’s withdrawal of 2025 financial outlook and recent leadership shakeup have added to the uncertainty.
- The analyst warns of a “kitchen sinking” approach—where the new CEO could reset expectations by absorbing all negatives upfront.
Wall Street Still Sees Value—For Now
Despite HSBC’s bearish view, UNH retains a Strong Buy consensus on Wall Street.
- Some analysts argue the stock’s 30% discount to its historical P/E offers a buying opportunity.
- However, concerns about Medicare Advantage profitability, Medicaid funding cuts, and delayed recovery into 2026–27 are starting to weigh on sentiment.
HSBC’s downgrade adds to a growing chorus of caution around UnitedHealth, once a market favorite. With earnings visibility clouded and regulatory risks looming, the stock may remain under pressure until the company can clarify its roadmap under new leadership.
